You can read here the whole post https://www.globenewswire.com/news-release/2024/05/22/2886202/0/en/deepull-appoints-Didier-Deltort-to-its-Board-of-Directors.html
Hospital Clínic Barcelona Collaborates with Mediktor for Improved Patient Assistance in Tropical Diseases
Read the full press release here: https://www.mediktor.com/es/news/news/hospital-clinic-barcelona-collaborates-with-mediktor-for-improved-patient-assistance-in-tropical-diseases
Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy
Read the full press release here: https://accure.health/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/
Peptomyc has been granted 40.000 € within the ACTIVA startups
Read the full press release here: Peptomyc has been granted 40.000 € within the ACTIVA startups
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
You can read full text here: https://www.globenewswire.com/news-release/2024/04/25/2869327/0/en/deepull-unveils-1-hour-direct-from-blood-multiplex-PCR-test-for-95-of-sepsis-causing-pathogens-at-ESCMID-2024.html
Why Your Company Needs an AI Assistant: Patient Engagement from First Contact
In an era where digital transformation is reshaping healthcare, the industry is experiencing a significant shift towards more patient-centered services. AI-based virtual assistance is at the forefront of this transformation, providing seamless, efficient, and personalized guidance at symptom onset. Its role in facilitating patient engagement is becoming increasingly indispensable for every stakeholder in the healthcare ecosystem. You can read the full article here: https://www.mediktor.com/es/news/news/why-your-company-needs-an-ai-assistant-patient-engagement-from-first-contact
Peptomyc Appoints Selwyn Ho to its Board of Directors
Barcelona, Spain, March 21st, 2024 Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors. Giacomo Di Nepi, Chairman of Peptomyc, says: “We are delighted to have Selwyn joining us. His impressive track record in the Healthcare sector, together with his experience in different executive…
Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours.
OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response markers. https://www.nature.com/articles/s41591-024-02805-1.epdf?sharing_token=Kb6gG5E9yqkeIKGERvlDs9RgN0jAjWel9jnR3ZoTv0PbA8JGCp8lm6FKJ7Jh-32YH7J2xVsk_KGC2EJRU1fEovpCc4NhoH9mLlaGUrqCoPgvJZNKyZVnNLFM1UXLoCexi1Zxi7bZ2rOl-ZxWgZOy8orQl2v1yuum2gO9zR0Zarg%3D
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
You can read the whole article here: https://mybinxhealth.com/news/binx-health-Enters-into-National-Distribution-Agreement-with-Cardinal-Health-to-Increase-Access
Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial